Endometriosis and cancer

H Kajiyama, S Suzuki, M Yoshihara, S Tamauchi… - Free Radical Biology …, 2019 - Elsevier
Endometriosis, characterized by the presence of extra-uterine endometrium, is a common
gynecologic disorder in reproductive-age women. Although the detailed molecular …

Clear cell carcinoma of the ovary: a clinical and molecular perspective

Y Iida, A Okamoto, RL Hollis, C Gourley… - International Journal of …, 2021 - ijgc.bmj.com
Clear cell carcinoma of the ovary has distinct biology and clinical behavior. There are
significant geographical and racial differences in the incidence of clear cell carcinoma …

Ovarian cancer, version 1.2016, NCCN clinical practice guidelines in oncology

RJ Morgan, DK Armstrong, RD Alvarez… - Journal of the National …, 2016 - jnccn.org
This selection from the NCCN Guidelines for Ovarian Cancer focuses on the less common
ovarian histopathologies (LCOHs), because new algorithms were added for LCOHs and …

[HTML][HTML] The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges

B Cheaib, A Auguste, A Leary - Chinese journal of cancer, 2015 - Springer
The phosphatidylinositol 3 kinase (PI3K) pathway is frequently altered in cancer, including
ovarian cancer (OC). Unfortunately, despite a sound biological rationale and encouraging …

Endometriosis-associated ovarian neoplasia

X Matias-Guiu, CJR Stewart - Pathology, 2018 - Elsevier
This article reviews the most relevant pathological and molecular features of ovarian
tumours that are associated with endometriosis. Endometriosis is a common condition …

Genomics to immunotherapy of ovarian clear cell carcinoma: unique opportunities for management

K Oda, J Hamanishi, K Matsuo, K Hasegawa - Gynecologic oncology, 2018 - Elsevier
Ovarian clear cell carcinoma (OCCC) is distinctive from other histological types of epithelial
ovarian cancer, with genetic/epigenetic alterations, a specific immune-related molecular …

[HTML][HTML] Chasing immune checkpoint inhibitors in ovarian cancer: novel combinations and biomarker discovery

I Colombo, K Karakasis, S Suku, AM Oza - Cancers, 2023 - mdpi.com
Simple Summary Immune checkpoint inhibitors (ICIs) have been investigated in epithelial
ovarian cancer in first-line and recurrent settings. When used as a single agent or in …

[HTML][HTML] Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives

S Mabuchi, T Sugiyama… - Journal of gynecologic …, 2016 - synapse.koreamed.org
Clear cell carcinoma (CCC) of the ovary is known to show poorer sensitivity to
chemotherapeutic agents and to be associated with a worse prognosis than the more …

[HTML][HTML] Carboplatin response in preclinical models for ovarian cancer: comparison of 2D monolayers, spheroids, ex vivo tumors and in vivo models

MN Brodeur, K Simeone, K Leclerc-Deslauniers… - Scientific reports, 2021 - nature.com
Epithelial ovarian cancer (EOC) is the most lethal gynecological cancer. Among the key
challenges in developing effective therapeutics is the poor translation of preclinical models …

Identification of somatic genetic alterations in ovarian clear cell carcinoma with next generation sequencing

Y Shibuya, H Tokunaga, S Saito… - Genes …, 2018 - Wiley Online Library
Ovarian clear cell carcinoma (OCCC) is the most refractory subtype of ovarian cancer and
more prevalent in Japanese than Caucasians (25% and 5% of all ovarian cancer …